Researchers looking to buy AOD-9604 are investigating one of the most selectively studied fragments of human Growth Hormone (hGH) for metabolic research. AOD-9604 (Advanced Obesity Drug, fragment hGH 176-191) is a modified peptide fragment corresponding to the C-terminal region of the hGH molecule — the portion associated with lipolytic (fat-breakdown) signalling — engineered to study this metabolic function while minimising the growth-promoting or insulin-sensitising effects of full-length hGH. EdgeChems supplies AOD-9604 for sale as an HPLC-verified research compound at ≥98% purity.
What Is AOD-9604?
AOD-9604 corresponds to amino acids 176-191 of the hGH sequence, with an additional tyrosine residue added at the N-terminus and a disulfide bond between Cys182 and Cys189. This fragment was isolated and modified by researchers at Monash University in Australia in the 1990s as part of a program to identify the specific region of hGH responsible for its fat-metabolism-regulating properties, independent of its anabolic and growth-promoting actions at the IGF-1 receptor.
The key research finding that drove AOD-9604 development was that the lipolytic activity of hGH does not require full-length hGH-receptor engagement — a specific C-terminal fragment retains lipid metabolism modulation properties while being largely inactive at the full GH receptor. This selectivity made AOD-9604 one of the first metabolic research peptides designed from mechanism-first, fragment-based principles.
Mechanisms of Action in Research Models
- Lipolysis stimulation: AOD-9604 activates lipolytic signalling in adipocyte cultures and animal models — stimulating the breakdown of stored triglycerides and increasing fatty acid release from fat cells via beta-3 adrenergic-like mechanisms independent of full hGH-receptor activation.
- Lipogenesis inhibition: Beyond stimulating fat breakdown, AOD-9604 research shows inhibition of new fat storage (lipogenesis) in adipocytes — a dual mechanism studied in obesity-related metabolic research.
- No IGF-1 stimulation: Unlike full-length hGH, AOD-9604 does not stimulate hepatic IGF-1 production in research models — important for researchers wishing to isolate fat metabolism effects without confounding anabolic or mitogenic signals.
- No glucose metabolism effects: AOD-9604 does not impair insulin sensitivity or glucose metabolism in animal studies — distinguishing it from full hGH for metabolic research protocols.
AOD-9604 Research History: From Peptide to Clinical Investigation
AOD-9604 progressed further through clinical development than most research peptides. After extensive animal safety and efficacy studies, it entered Phase 1 and Phase 2 clinical trials in the early 2000s for obesity treatment. Phase 2b and Phase 3 trials were ultimately discontinued due to insufficient clinical efficacy at doses studied — but the safety profile in human trials was notably clean, with no significant adverse events at doses up to 1mg/kg. The compound was granted GRAS (Generally Recognized As Safe) status by the FDA in 2014 as a food ingredient, based on the clinical safety data accumulated during its development — an unusual regulatory distinction for a research peptide.
BAM-15: A Related Mitochondrial Uncoupler for Metabolic Research
Researchers investigating metabolic peptides may also be interested in BAM-15 — a mitochondrial uncoupler that increases cellular energy expenditure by dissipating the mitochondrial proton gradient. BAM-15 represents a mechanistically distinct approach to metabolic research compared to AOD-9604, operating at the mitochondrial membrane level rather than via adipocyte receptor signalling. EdgeChems supplies BAM-15 for researchers studying metabolic rate modulation and mitochondrial biology.
Product Specifications — Buy AOD-9604 From EdgeChems
- Compound: AOD-9604 (hGH fragment 176-191)
- Format: Liquid solution
- Purity: ≥98% (third-party HPLC verified)
- CAS Number: 221231-10-3
- Molecular Weight: 1817.1 g/mol
- Storage: -20°C, protected from light
- Stability: 24 months sealed
Order AOD-9604 for sale from EdgeChems with third-party HPLC COA on every batch.
Research Applications Summary
- Adipocyte lipolysis and fat metabolism signalling studies
- Lipogenesis inhibition and fat storage regulation research
- Metabolic obesity research in animal models
- Selective hGH fragment pharmacology studies
- Metabolic rate and energy expenditure research models
For research purposes only. Not intended for human or veterinary use. All information is presented for scientific reference.